Clinical

Dataset Information

0

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer


ABSTRACT: This is a multicenter observational study aimed to describe the efficacy and safety of regorafenib plus programmed cell death-1 (PD-1) inhibitors in Chinese patients with advanced colorectal cancer in routine clinical practice. The primary end point is overall survival. The secondary endpoints include progression-free survival, objective response rate, disease control rate and the incidence of treatment-related adverse events.

DISEASE(S): Advanced Colorectal Carcinoma,Colorectal Neoplasms

PROVIDER: 2368689 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-01-22 | PXD048448 |
| S-EPMC5323130 | biostudies-literature
| 92574 | ecrin-mdr-crc
| S-EPMC7481633 | biostudies-literature
| PRJNA479408 | ENA
| S-EPMC6803548 | biostudies-literature
2013-11-14 | E-GEOD-49108 | biostudies-arrayexpress
| S-EPMC6582789 | biostudies-literature
2013-05-08 | E-GEOD-45752 | biostudies-arrayexpress
| S-EPMC6474755 | biostudies-literature